Dupilumab after sequential omalizumab and benralizumab failure in T2-high asthma–COPD overlap: A case report
Main Article Content
Keywords
biologic switching, corticosteroid sparing, exacerbation prevention, interleukin-4 receptor alpha, type-2 inflammation
Abstract
Asthma–COPD overlap (ACO) remains therapeutically challenging, and evidence for biologic selection is limited due to the under-representation of overlap phenotypes in trials. We report a T2-high ACO patient who did not benefit from omalizumab or benralizumab but improved with dupilumab. This presents the case of a 67-year-old man with a long-term smoking history, atopy (elevated total IgE with polysensitization), eosinophilia, persistent airflow limitation, and frequent exacerbations despite optimized inhaled triple therapy. Sequential biologics included anti-IgE (omalizumab) and anti-IL-5Rα (benralizumab), with no meaningful reduction in exacerbations or improvement in lung function. After initiating dupilumab at a dose of 300 mg every 2 weeks, the patient reported a rapid improvement in symptoms, with no further exacerbations observed during the follow-up period. Pulmonary function showed a notable increase, with postbronchodilator FEV1 rising from 61 to 72% of the predicted value, and FEV1/ FVC ratio improving from 69 to 84.5%. Asthma control scores increased from 12 to 20 by Week 12. Oral corticosteroid therapy was successfully discontinued, and no adverse events requiring discontinuation of dupilumab were recorded. In T2-high ACO unresponsive to anti-IgE and anti-IL-5Rα therapies, IL-4/IL-13 pathway inhibition with dupilumab may deliver a clinically meaningful benefit. Controlled studies are warranted to define its role in overlap phenotypes.
References
2. Toledo-Pons N, van Boven JFM, Román-Rodríguez M, Pérez N, Valera Felices JL, Soriano JB, et al. ACO: Time to move from the description of different phenotypes to the treatable traits. PLoS One. 2019;14(1):e0210915. https://doi.org/10.1371/journal.pone.0210915
3. Joo H, Kim L, Park SY, Kim SH, Cho YS, Chang YS, et al. Phenotype of asthma-COPD overlap in COPD and severe asthma cohorts. J Korean Med Sci. 2022;37(30):e236. https://doi.org/10.3346/jkms.2022.37.e236
4. Kavanagh JE, Hearn AP, Dhariwal J, d'Ancona G, Douiri A, Roxas C, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. https://doi.org/10.1016/j.chest.2020.08.2083
5. Hanania NA, Chipps BE, Griffin NM, Yoo B, Iqbal A, Casale TB. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019;143(4):1629–33.e2. https://doi.org/10.1016/j.jaci.2018.11.032
6. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96. https://doi.org/10.1056/NEJMoa1804092
7. Cai H, Chen ZX, Ji HY, Shen QJ, Bi J, Tong L, et al. The clinical use of dupilumab for elderly patients with severe COPD exacerbations: A case series. Arch Bronconeumol. Published online March 20, 2025. https://doi.org/10.1016/j.arbres.2025.03.005
8. Kodaka N, Nakano C, Oshio T, Hirouchi T, Yamada Y, Matsuse H. Effects of dupilumab for asthma-chronic obstructive pulmonary disease overlap. Iran J Allergy Asthma Immunol. 2023;22(2):212–6. https://doi.org/10.18502/ijaai.v22i2.12683
9. Tat TS, Cilli A. Omalizumab treatment in asthma-COPD overlap syndrome. J Asthma. 2016;53(10):1048–50. https://doi.org/10.1080/02770903.2016.1178281
10. Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: A randomised, double-blind, placebo controlled, phase 2a study. Lancet Respir Med. 2014;2(11):891–901. https://doi.org/10.1016/S2213-2600(14)70187-0